Investegate |Sanofi - Aventis Groupe Announcements | Sanofi - Aventis Groupe: Press Release: Fitusiran prophylaxis reduced bleeds by 61% in people with hemophilia A or B, with or without inhibitors, compared to prior factor or bypassing agent prophylaxis

Investegate announcements from Sanofi - Aventis Groupe, Press Release: Fitusiran prophylaxis reduced bleeds by 61% in people with hemophilia A or B, with or without inhibitors, compared to prior factor or bypassing agent prophylaxis

Related Keywords

Paris ,France General ,France ,Israel ,Tel Aviv ,Eva Schaefer Jansen ,Corentine Driancourt ,Felix Lauscher ,Nathalie Pham ,Sally Bain ,Gili Kenet ,Priya Nanduri ,Global Head Of Development ,International Society On Thrombosis ,Alnylam Pharmaceutical Inc ,Nasdaq ,Euronext ,Press Release ,International Society ,Israeli National Hemophilia Center ,Sheba Medical Center ,Amalia Biron Thrombosis Research Institute ,Tel Aviv University ,Chief Medical ,Alnylam Pharmaceutical ,Private Securities Litigation Reform Act ,Statement Regarding Forward Looking ,Investegate Announcements ,Investegate Company Announcements ,Sanofi Aventis Groupe ,Lobenewswire ,Lobenewswire And Globenewswire ,Nw ,